tetano
Editor, Senior Moderator
BMJ Open
. 2025 Aug 3;15(8):e101050.
doi: 10.1136/bmjopen-2025-101050. Multicentre, prospective, single-arm, non-controlled, open-label trial to evaluate the safety and efficacy of live attenuated influenza vaccine in paediatric patients with atopic dermatitis undergoing dupilumab therapy: a protocol
Toshiyuki Kobayashi[SUP] 1 [/SUP], Hironori Sato[SUP] 1 [/SUP], Koo Nagasawa[SUP] 2 [/SUP], Eri Hayata[SUP] 1 [/SUP], Saori Tanaka[SUP] 1 [/SUP], Erika Kurihara[SUP] 1 [/SUP], Takeshi Yamamoto[SUP] 1 [/SUP], Taiji Nakano[SUP] 1 [/SUP], Yoshihito Ozawa[SUP] 3 [/SUP], Fumiya Yamaide[SUP] 4 [/SUP], Yuzaburo Inoue[SUP] 5 6 [/SUP], Shuichi Suzuki[SUP] 7 [/SUP], Takayasu Arima[SUP] 8 [/SUP], Minako Tomiita[SUP] 9 [/SUP], Hiromichi Hamada[SUP] 1 [/SUP], Naruhiko Ishiwada[SUP] 10 [/SUP]
Affiliations
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin condition that impairs the quality of life of affected paediatric patients and their families. Dupilumab, an antagonist of the shared alpha chain subunit of the cytokines interleukin-4 and interleukin-13, has revolutionised the management of moderate-to-severe AD by effectively targeting type 2 inflammation. However, live attenuated vaccines, including live attenuated influenza vaccines (LAIVs), are contraindicated during dupilumab therapy owing to limited safety data. This restriction poses challenges to immunisation strategies, particularly in paediatric populations. This study aims to evaluate the safety and efficacy of LAIV in paediatric patients with AD undergoing dupilumab therapy.
Method and analysis: This multicentre, prospective, single-arm, open-label trial will enrol 50 paediatric patients aged 2-18 years with AD undergoing dupilumab treatment. The participants will receive intranasal LAIV, followed by a 25-week observation period after vaccination. The primary outcome is the proportion of participants with a four-fold or greater increase in haemagglutination inhibition titres against influenza strains A(H1N1), A(H3N2) and B at 4 weeks post vaccination. The secondary outcomes include the incidence of influenza and systemic or local adverse events, such as injection site reactions, fever and other influenza-like symptoms observed within 4 weeks of vaccination. Exploratory endpoints include the evaluation of immunosuppressive markers such as neutrophil counts, lymphocyte subsets and serum immunoglobulin G levels. Safety analyses will assess the frequency of each adverse event, whereas efficacy analyses will focus on immunogenicity and influenza incidence during the 25-week follow-up period. This study aims to provide critical safety and immunogenicity data to guide immunisation strategies in biologically treated paediatric patients with AD.
Ethics and dissemination: This study complies with the principles of the Declaration of Helsinki and received ethics approval from the Institutional Review Board of Chiba University Hospital as a specified clinical trial. Informed consent and assent will be obtained as appropriate based on the participants' ages. These findings will be disseminated through peer-reviewed journals and scientific conferences to inform clinical vaccination strategies for biologically treated populations.
Trial registration number: jRCTs031240442.
Keywords: IMMUNOLOGY; PAEDIATRICS; Safety; VIROLOGY; Vaccination.
. 2025 Aug 3;15(8):e101050.
doi: 10.1136/bmjopen-2025-101050. Multicentre, prospective, single-arm, non-controlled, open-label trial to evaluate the safety and efficacy of live attenuated influenza vaccine in paediatric patients with atopic dermatitis undergoing dupilumab therapy: a protocol
Toshiyuki Kobayashi[SUP] 1 [/SUP], Hironori Sato[SUP] 1 [/SUP], Koo Nagasawa[SUP] 2 [/SUP], Eri Hayata[SUP] 1 [/SUP], Saori Tanaka[SUP] 1 [/SUP], Erika Kurihara[SUP] 1 [/SUP], Takeshi Yamamoto[SUP] 1 [/SUP], Taiji Nakano[SUP] 1 [/SUP], Yoshihito Ozawa[SUP] 3 [/SUP], Fumiya Yamaide[SUP] 4 [/SUP], Yuzaburo Inoue[SUP] 5 6 [/SUP], Shuichi Suzuki[SUP] 7 [/SUP], Takayasu Arima[SUP] 8 [/SUP], Minako Tomiita[SUP] 9 [/SUP], Hiromichi Hamada[SUP] 1 [/SUP], Naruhiko Ishiwada[SUP] 10 [/SUP]
Affiliations
- PMID: 40754333
- PMCID: PMC12320056
- DOI: 10.1136/bmjopen-2025-101050
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin condition that impairs the quality of life of affected paediatric patients and their families. Dupilumab, an antagonist of the shared alpha chain subunit of the cytokines interleukin-4 and interleukin-13, has revolutionised the management of moderate-to-severe AD by effectively targeting type 2 inflammation. However, live attenuated vaccines, including live attenuated influenza vaccines (LAIVs), are contraindicated during dupilumab therapy owing to limited safety data. This restriction poses challenges to immunisation strategies, particularly in paediatric populations. This study aims to evaluate the safety and efficacy of LAIV in paediatric patients with AD undergoing dupilumab therapy.
Method and analysis: This multicentre, prospective, single-arm, open-label trial will enrol 50 paediatric patients aged 2-18 years with AD undergoing dupilumab treatment. The participants will receive intranasal LAIV, followed by a 25-week observation period after vaccination. The primary outcome is the proportion of participants with a four-fold or greater increase in haemagglutination inhibition titres against influenza strains A(H1N1), A(H3N2) and B at 4 weeks post vaccination. The secondary outcomes include the incidence of influenza and systemic or local adverse events, such as injection site reactions, fever and other influenza-like symptoms observed within 4 weeks of vaccination. Exploratory endpoints include the evaluation of immunosuppressive markers such as neutrophil counts, lymphocyte subsets and serum immunoglobulin G levels. Safety analyses will assess the frequency of each adverse event, whereas efficacy analyses will focus on immunogenicity and influenza incidence during the 25-week follow-up period. This study aims to provide critical safety and immunogenicity data to guide immunisation strategies in biologically treated paediatric patients with AD.
Ethics and dissemination: This study complies with the principles of the Declaration of Helsinki and received ethics approval from the Institutional Review Board of Chiba University Hospital as a specified clinical trial. Informed consent and assent will be obtained as appropriate based on the participants' ages. These findings will be disseminated through peer-reviewed journals and scientific conferences to inform clinical vaccination strategies for biologically treated populations.
Trial registration number: jRCTs031240442.
Keywords: IMMUNOLOGY; PAEDIATRICS; Safety; VIROLOGY; Vaccination.